Cytokine Signalling Forum

Publications





June 19

Impacto de los Inhibidores de Janus Quinasa en el Riesgo de Eventos Cardiovasculares en Pacientes con Artritis Reumatoide: Revisión Sistemática y Metaanálisis de Ensayos Controlados Aleatorizados

Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z.
Ann Rheum Dis. 2019 Aug;78(8):1048-1054.

Existing evidence from RCTs indicated no significant change in CV risk for JAK inhibitor (JAKinib) treated RA patients in a short-term perspective compared to placebo. Patients with RA have an elevated risk of CV morbidity and mortality, which cannot be fully explained by traditional CV risk factors. Reaching remission or LDA in order to reduce CV events (CVE) is encouraged in the current EULAR recommendations. JAKinibs and their roles in the modulation of CV risk remain undetermined. This stud...

Keywords: JAK, Baricitinib, Clinical, Safety

Translated by: Igor

April 19

Tuberculosis, Hepatitis B y Herpes Zoster en Pacientes con Artritis Reumatoide tratados con Tofacitinib

Zhang Z, Deng W, Wu Q, Sun L.
Immunotherapy. 2019 Mar;11(4):321-333.

The risk of TB and hepatitis B virus (HBV) appears to be no greater with TOF than with bDMARDs. Most cases of TB during TOF studies occurred in regions with high background rate of TB, including east Asian countries. TOF is also associated with a higher rate of herpes zoster (HZ) compared with bDMARDs. DMARDs used to treat RA can increase the risk of infections by causing a degree of immunosuppression. A range of bacterial and viral infections have been observed in association with DMARD thera...

Keywords: JAK, Tofacitinib, Clinical, Safety

Translated by: Igor